DE60041880D1 - Verfahren zur verbesserung der chemotherapie - Google Patents

Verfahren zur verbesserung der chemotherapie

Info

Publication number
DE60041880D1
DE60041880D1 DE60041880T DE60041880T DE60041880D1 DE 60041880 D1 DE60041880 D1 DE 60041880D1 DE 60041880 T DE60041880 T DE 60041880T DE 60041880 T DE60041880 T DE 60041880T DE 60041880 D1 DE60041880 D1 DE 60041880D1
Authority
DE
Germany
Prior art keywords
improving chemotherapy
cell proliferative
proliferative disorder
chemotherapy
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041880T
Other languages
German (de)
English (en)
Inventor
Michael James Newman
William Ross Dixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAIJI BIOMEDICAL, INC., PALO ALTO, CALIF., US
Original Assignee
Taiji Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiji Biomedical Inc filed Critical Taiji Biomedical Inc
Application granted granted Critical
Publication of DE60041880D1 publication Critical patent/DE60041880D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60041880T 1999-10-08 2000-10-06 Verfahren zur verbesserung der chemotherapie Expired - Lifetime DE60041880D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15832299P 1999-10-08 1999-10-08
PCT/US2000/027612 WO2001026467A1 (en) 1999-10-08 2000-10-06 Methods of enhancing chemotherapy

Publications (1)

Publication Number Publication Date
DE60041880D1 true DE60041880D1 (de) 2009-05-07

Family

ID=22567591

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041880T Expired - Lifetime DE60041880D1 (de) 1999-10-08 2000-10-06 Verfahren zur verbesserung der chemotherapie

Country Status (7)

Country Link
EP (2) EP2064951A1 (https=)
JP (1) JP2003511396A (https=)
AT (1) ATE426335T1 (https=)
AU (1) AU782401B2 (https=)
CA (1) CA2382727A1 (https=)
DE (1) DE60041880D1 (https=)
WO (1) WO2001026467A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084543A1 (en) 2002-04-10 2003-10-16 Virginia Commonwealth University Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
AU2003257329C1 (en) 2002-08-19 2010-07-22 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
AU2006250809B2 (en) 2005-05-25 2011-05-12 Lorus Therapeutics Inc. 2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer
EP2454943B1 (en) 2010-11-23 2020-05-27 GEA Food Solutions Bakel B.V. Apparatus and method for the production of a product with an interleaver
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
ES2775579T3 (es) 2013-10-04 2020-07-27 Aptose Biosciences Inc Composiciones para el tratamiento del cáncer
LU100887B1 (en) 2017-02-24 2018-12-18 Bioactor B V Compounds and compositions against visceral hypersensitivity
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors
WO2025119974A1 (en) 2023-12-04 2025-06-12 Bioactor Bv Naringin or naringenin for improving sleep quality

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
US5756527A (en) * 1995-06-07 1998-05-26 Ontogen Corporation Imidazole derivatives useful as modulators of multi drug resistances
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators

Also Published As

Publication number Publication date
AU7866100A (en) 2001-04-23
EP1221847B1 (en) 2009-03-25
CA2382727A1 (en) 2001-04-19
ATE426335T1 (de) 2009-04-15
EP1221847A4 (en) 2006-03-22
AU782401B2 (en) 2005-07-28
EP2064951A1 (en) 2009-06-03
WO2001026467A1 (en) 2001-04-19
JP2003511396A (ja) 2003-03-25
EP1221847A1 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
DE60226912D1 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
DE122011100040I2 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.
EP1622616A4 (en) HEMMER OF ACT ACTIVITY
DE60041880D1 (de) Verfahren zur verbesserung der chemotherapie
EP1631548A4 (en) HEMMER OF ACT ACTIVITY
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
DK1159279T3 (da) 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
EE9500034A (et) Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine
BRPI0116967A2 (pt) derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
DK1056704T3 (da) Antitumormidler
ES2013403A6 (es) Procedimiento para preparar derivados de cefem.
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BR0311136A (pt) composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
WO2004075858A3 (en) Flavone acetic acid analogs and methods of use thereof
DE60113838D1 (de) Derivate von triterpen-säuren
AR026222A1 (es) Compuestos derivados de acido antranilico
MXPA05012360A (es) Derivados de benzotiazol como ligandos receptores de adenosina.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TAIJI BIOMEDICAL, INC., PALO ALTO, CALIF., US

8364 No opposition during term of opposition